Key result
Pediatric VAD implantation is linked to increased cardiac ADPN receptor expression without altering circulating levels.
Why the study?
The effect of ventricular assist device implant on the adiponectin system and its regulation by microRNAs in pediatric heart failure patients was not well understood.
Does VAD implantation modify the adiponectin system and related miRNAs in pediatric patients with end-stage heart failure?
Observational
Does VAD implantation modify the adiponectin system and related miRNAs in pediatric patients with end-stage heart failure?
VAD implantation in pediatric heart failure upregulates cardioprotective adiponectin receptors, potentially mediated by epigenetic regulation via miRNAs.
Answers are grounded in this paper and cite their sources.
VAD may upregulate cardiac ADPN receptors via miRNAs in pediatric HF; leaves open whether targeting these miRNAs improves outcomes.
Background: Ventricular assist device (VAD) implant represents a therapeutic option for pediatric patients with end-stage heart failure (HF). Heart unloading by VAD can modify several molecular pathways underlying cardiac function in HF. Among them, the potential role of microRNA (miRNAs) in response to VAD implant is emerging. This study was aimed at investigating in HF pediatric patients the effect of VAD-modified miRNAs on the adiponectin (ADPN) system, known to exert cardioprotective actions. Methods: ADPN was measured in plasma samples obtained from HF children, before and 1 month after VAD implant, and from healthy control children. miRNA profile and molecules belonging to ADPN system were determined in cardiac biopsies collected at the time of VAD implantation (pre-VAD) and at the moment of heart transplant (post-VAD). An in vitro study using HL-1 cell line was performed to verify the regulatory role of the VAD-modified miRNA on the ADPN system. Results: VAD implant did not affect circulating and cardiac levels of ADPN, but increased the cardiac mRNA expression of ADPN receptors, including AdipoR1, AdipoR2, and T-cad. AdipoR2 and T-cad were inversely related to the VAD-modified miRNA levels. The in vitro study confirmed the regulatory role of miR-1246 and miR-199b-5p on AdipoR2, and of miR-199b-5p on T-cad. Conclusions: These data suggest that VAD treatment could regulate the expression of the cardioprotective ADPN system by epigenetic mediators, suggesting that miRNAs have a potential role as therapeutic targets to improve cardiac function in HF pediatric patients.
No takes yet. Share an insight, caveat, or question.
Ragusa et al. (2023) conducted an observational in End-stage heart failure. Ventricular assist device (VAD) implant vs. Pre-VAD baseline and healthy controls was evaluated on Adiponectin (ADPN) system levels and miRNA profile. Ventricular assist device implantation in pediatric heart failure increased cardiac mRNA expression of ADPN receptors (AdipoR1, AdipoR2, T-cad) without affecting circulating ADPN levels.
Synapse has enriched 10 related papers. Consider them for comparative context: